TrialCell reports. Medicine2024

Camu-camu decreases hepatic steatosis and liver injury markers in overweight, hypertriglyceridemic individuals: A randomized crossover trial.

Anne-Laure Agrinier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.